Pfizer-BioNTech COVID-19 vaccine overview and safety (also known as COMIRNATY)

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Oct. 28, 2021 ; Pfizer-BioNTech (COMIRNATY) Name Change ; Pfizer-BioNTech (COMIRNATY) received U.S. Food and Drug Administration (FDA) approval on August 23, 2021, for individuals 16 years of age and older. Once vaccines are approved by the FDA, companies can market the vaccines under brand names. COMIRNATY is the brand name for the Pfizer-BioNTech COVID-19 Vaccine. Now that the FDA-authorized Pfizer-BioNTech COVID-19 vaccine has been approved by the FDA for individuals 16 years of age and older, it will be marketed as COMIRNATY. The use of the name Pfizer-BioNTech will still be used for individuals 12-15 years old since this age group has not been approved. There has been no change in the formulation of the vaccine since the name change.
• Subjects:
  • COVID-19 Vaccines
  • COVID-19/prevention & control
  • Coronavirus Infections/prevention & control
  • Immunization, Secondary
  • Vaccines
• Document Type:
  Webpage
• Corporate as Subject:
  Pfizer-BioNTech COVID-19 vaccine ; COMIRNATY
• Download URL:
  https://stacks.cdc.gov/view/cdc/111109/cdc_111109_DS1.pdf
• File Type:
  [PDF - 718.21 KB]
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:7cb2ede38b514ee2bf17d1548d13bcbb7367c6670d08daa466d629bfa9165acb